Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction

Figures

• 

  Figure 1. Plasma S100A12 levels and diagnostic accuracy. Baseline plasma S100A12 concentrations at the time of hospital arrival to the emergency department were measured by ELISA in the diagnosis cohort. (A) Bars and limit lines represent the mean ± SD. UAP, unstable angina pectoris; PTE, pulmonary thromboembolism; AD, aortic dissection; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction. (B) Area under the curve (AUC) for S100A12, high-sensitivity cardiac troponin T (hscTnT), creatine kinase MB isoenzyme (CK-MB) in STEMI patients. *P < 0.05 compared with all other groups.

• 

  Figure 2. Time trends of plasma S100A12, CK-MB and hscTnT levels in patients with STEMI. *Represents the time point when plasma concentration was first higher than the diagnostic critical value. Chest pain time ≤ 30 min included 9 STEMI patients (a total of 9 samples were measured); chest pain time of 30 min to 1 h included 28 STEMI patients (a total of 37 samples were measured); and chest pain time of 1–2 h included 113 STEMI patients (a total of 150 samples were measured). Samples from all 150 patients were tested at each subsequent time after 2 h. Bars and limit lines represent the mean ± SEM.

• 

  Figure 3. Diagnostic accuracy of S100A12 in patients presenting within 2 h of symptom onset; (A) Plasma concentration of S100A12 in patients with a final adjudicated diagnosis of STEMI, NSTMI, UAP and others; (B) The AUC for S100A12, hscTnT, and CK-MB in the STEMI cohort presenting ≤ 2 h after symptom onset (n = 150). UAP, unstable angina pectoris; PTE, pulmonary thromboembolism; AD, aortic dissection; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.